Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Abri SPAC I, Inc (ASPAU) Announces 5M Unit IPO at $10/unit
-
IPO for SPAC CleanTech Acquisition Corp. (CLAQ) Opens at $10.02
-
CleanTech Acquisition Corp (CLAQU) Prices 15M Unit IPO at $10/unit
-
CleanTech Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
CleanTech Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
Form PRER14A Chardan Healthcare Acqui
-
Form S-1/A Chardan NexTech Acquisit
-
Chardan Capital Markets Starts Femasys Inc. (FEMY) at Buy
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan Names Gbola Amusa, MD, CFA Chief Scientific Officer
-
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance
-
Tenaya Therapeutics, Inc (TNYA) Files up to $100M IPO
-
CHW Acquisition Corporation (CHWAU) Announces 10M Unit IPO at $10/unit
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors
-
Intellia Therapeutics (NTLA) PT Raised to $130 at Chardan Capital Markets
-
CLEANTECH ACQUISITION CORP (CLAQU) Announces 15M Unit IPO at $10/unit
-
Pear Therapeutics to Become Public Company via Merger with Thimble Point Acquisition Corp. (THMA)
-
Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition (BCYP)
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg
-
Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO
-
Femasys (FEMY) IPO Opens Flat
-
Femasys Inc. Announces Pricing of Initial Public Offering
-
Femasys Inc. Announces Pricing of Initial Public Offering
-
PLBY Group Announces Closing of Public Offering of Common Stock
-
Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets
-
PLBY Group (PLBY) Prices 4.72M Share Upsized Common Offering at $46/Sh
-
PLBY Group Announces Upsize and Pricing of Public Offering of Common Stock
-
PDS Biotechnology Corp (PDSB) PT Raised to $15 at Chardan Capital Markets
-
SPK Acquisition Corp. (SPK) Prices 5M Unit IPO at $10/Unit
-
SPK Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
-
PLBY Group (PLBY) Announced Proposed Offering of 4M Shares
-
PLBY Group Announces Proposed Public Offering of Common Stock
-
PLBY Group (PLBY) Files to Offer 4M Shares of Common Stock
-
Form S-1/A Chardan NexTech Acquisit
-
Form PREM14A Chardan Healthcare Acqui For: Jun 03
-
Chardan Capital Markets Assumes Axcella Health Inc. (AXLA) at Buy
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer
-
Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets Following FDA AdComm Vote
-
Form 10-Q Chardan Healthcare Acqui For: Mar 31
-
Mountain Crest Acquisition Corp. III Announces Closing of $50 Million Initial Public Offering
-
PDS Biotechnology Corp (PDSB) PT Raised to $11 at Chardan Capital Markets
-
Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay
-
IPO for SPAC Mountain Crest Acquisition Corp. III (MCAE) Opens Flat at $10
-
Mountain Crest Acquisition Corp. III (MCAE) Prices 5M Unit IPO at $10/Unit
-
Mountain Crest Acquisition Corp. III Announces Pricing of $50 Million Initial Public Offering
-
Form NT 10-Q Chardan Healthcare Acqui For: Mar 31

